Neurological Disorders

Specialty biopharma company PharmaTher Holdings Ltd. (OTCQB: PHRRF) has entered into an evaluation and exclusive option agreement with Case Western Reserve University (CWRU) for the development and commercialization of the IP of ketamine for the treatment of the Rett Syndrome (RTS), a rare genetic...

Life sciences company Revive Therapeutics Ltd. (OTCQB: RVVTF) is advancing its first Phase I/II clinical trial of oral psilocybin for methamphetamine use disorder treatment while also developing an oral psilocybin thin film strip product. Revive is currently studying psilocybin’s potential as...

Biotech psychedelics researcher and developer Silo Pharma Inc. (OTCQB: SILO) announced its topically-administered proprietary ketamine obtained a positive outcome in a recent preclinical study. The trial has then proven the combination of Silo’s ketamine together with Zylo’s delivery...

Tesla Inc (NASDAQ: TSLA) CEO Elon Musk's startup Neuralink brain chip could help treat morbid obesity; that's what Musk believes. Echoing Musk's statement, scientists say it's not an impossibility.  Responding to a Twitter post on the same line, Musk said that it is...

UniQure N.V. (NASDAQ: QURE) has agreed to acquire Corlieve Therapeutics and its lead program for temporal lobe epilepsy (TLE), the most common form of focal epilepsy. The company will pay €46.3 million in an upfront cash payment. Corlieve shareholders are eligible to receive up...

CRISPR Therapeutics (NASDAQ: CRSP) has signed a deal with Capsida Biotherapeutics, a gene therapy player specializing in AAV engineering, to carve out a delivery mechanism for the company’s gene-editing technology in familial amyotrophic lateral sclerosis (ALS) and rare...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorizations for Bluebird bio Inc’s (NASDAQ: BLUE) Skysona (elivaldogene autotemcel) new gene therapy for children with a rare, inherited neurological...

Ovid Therapeutics Inc (NASDAQ: OVID) has announced to discontinue the development of OV101 (gaboxadol), a delta (δ)-selective GABAA receptor agonist, in Angelman syndrome and Fragile X syndrome. The company says that while OV101 was well tolerated, with no significant...